Tag: hyaluronic acid

PRP Injections and Their Benefits for Osteoarthritis

Discover the potential of PRP injections for osteoarthritis treatment and its role in promoting healing and reducing inflammation.

Abstract

As a clinician dedicated to integrative and evidence-based care, I frequently encounter patients suffering from knee osteoarthritis (OA) who are seeking relief. The decision on which injectable treatment to use can be complex, involving a delicate balance of providing rapid pain relief, ensuring long-term joint health, and considering the patient’s individual needs and goals. In this educational post, I will guide you through the latest research on common intra-articular injections for knee OA. We will begin by examining the role and significant risks of corticosteroids, exploring why the medical community is moving toward alternatives. I will then introduce ketorolac, an NSAID injection, as a safer, fast-acting alternative for acute flares. We’ll delve into the science of hyaluronic acid (HA), or viscosupplementation, evaluating its potential for longer-term benefits and its current standing in clinical guidelines. Finally, we will explore the exciting and robust evidence supporting Platelet-Rich Plasma (PRP) as a treatment that not only manages pain but also shows promise as a disease-modifying therapy capable of delaying the need for surgery. Throughout this discussion, I will integrate my clinical observations and emphasize how an integrative chiropractic approach, focusing on biomechanics and holistic patient care, complements these advanced treatments to optimize outcomes for our patients.

---

Hello, I’m Dr. Alexander Jimenez. With my extensive background in chiropractic and functional medicine, holding titles such as DC, APRN, FNP-BC, CFMP, IFMCP, ATN, and CCST, my practice is rooted in a deep commitment to providing integrative care grounded in the latest scientific evidence. Today, I want to take you on a journey through the landscape of injectable treatments for knee osteoarthritis, a condition I see daily in my clinic. We’ll examine what the research tells us and how we can make the best choices for our patients.

Let’s begin with a common clinical scenario to frame our discussion.

A Common Clinical Scenario: The Acute Knee OA Flare

Imagine a 60-year-old woman who comes into my office with an acute flare-up of her right knee pain. She was diagnosed with mild osteoarthritis two years prior and had managed it well with physical therapy and weight loss. She remains quite active, but this current flare started after a bit more walking than usual. There was no specific injury or trauma. She presents with mild swelling, and her pain is most pronounced when using stairs. Her son’s wedding is just a week away, and she is understandably anxious, requesting an injection to improve her pain and mobility for the event.

On examination, she has a mild antalgic gait (walking with a limp to avoid pain), tenderness along the medial joint line, and a small effusion (swelling within the joint). Her X-rays confirm tricompartmental osteoarthritis with a Kellgren-Lawrence (K-L) grade of 2, which is considered mild to moderate.

So, we have a patient with an acute OA flare, no history of prior injections, and a significant life event approaching. What is the best way to help her? The most conventional response in many practices would be an intra-articular corticosteroid injection. But is that the right answer? My goal today is not to give you a single “correct” answer but to arm you with the evidence so you can make an informed decision, one that aligns with the principles of modern, evidence-based care.

The Double-Edged Sword of Corticosteroid Injections

Why Corticosteroids are so Common

There’s a clear reason why corticosteroids have been the go-to for decades. The primary driver of pain and swelling in an OA flare is synovial inflammation. Corticosteroids are potent anti-inflammatory agents. They work by:

• Suppressing the infiltration of leukocytes (white blood cells) into the joint.
• Decreasing the activity of local immune cells within the synovium (the soft tissue lining the joint).
• Downregulating the expression of genes involved in the inflammatory cascade.

This powerful anti-inflammatory effect leads to decreased synovial membrane inflammation and a reduction in the effusion. The result is rapid pain relief, typically occurring within three to seven days. For our patient with the wedding next week, this timeline is very appealing. While oral NSAIDs or steroids could be considered, they carry significant systemic risks that an injection helps to minimize.

The Mounting Evidence Against Corticosteroids

Despite the short-term benefits, a growing body of evidence urges caution. There is significant concern for chondrotoxicity, meaning the substance is toxic to cartilage cells. Preclinical studies have provided robust evidence that steroids exert dose-dependent deleterious effects on cartilage morphology, histology, and viability. Simply put, the higher the dose of the steroid, the more damage it can cause to the cartilage. Among the different types, dexamethasone and triamcinolone appear to be the least toxic, but the risk remains.

This isn’t just a finding in lab studies. High-level clinical trials support these concerns. A pivotal study published in JAMA in 2017 was a two-year, randomized, placebo-controlled trial comparing injections of triamcinolone to saline in patients with knee OA (McAlindon et al., 2017). Patients received an injection every 12 weeks. The findings were startling:

• There was no significant difference in pain relief between the steroid group and the placebo (saline) group over the two years.
• The group receiving repeated steroid injections experienced significantly greater cartilage volume loss compared to the placebo group.

Another powerful retrospective review of over 49,000 patients, published in 2019, found that patients who received even one to three steroid injections (for various hip or knee conditions, not just OA) had a twofold greater risk of needing a knee replacement at the five-year mark (Kompel et al., 2019). The study also revealed a dose-dependent relationship: the risk of total knee arthroplasty (TKA) increased with each subsequent injection.

In my clinical practice at ChiroMed, I’ve observed this pattern. Patients who have received multiple steroid injections over the years often present with more advanced degenerative changes on their imaging than their symptom history might suggest. This is why there is a strong call within the medical community to find safer alternatives. While a single, first-time injection for an acute flare might seem reasonable, we must ask ourselves if we are sacrificing long-term joint health for short-term relief.

Ketorolac: A Safer, Fast-Acting Alternative for Knee Flares

If we want to avoid the chondrotoxic effects of steroids but still provide rapid relief for a patient like the one we discussed, where do we turn? I want to present an excellent alternative: ketorolac.

Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) that can be injected directly into the joint. Its mechanism of action is different from and safer than corticosteroids:

• As a COX-1 and COX-2 inhibitor, it blocks prostaglandin production, which is a key mediator of inflammation and pain sensitization.
• Delivering it locally via injection achieves a high concentration in the synovial fluid, providing potent anti-inflammatory effects with minimal systemic exposure compared with oral NSAIDs.
• Crucially, ketorolac provides anti-inflammatory and analgesic effects without the immunosuppressive and gene-expression-altering effects of steroids.

Most importantly, preclinical models have not shown the deleterious structural effects on cartilage that we see with steroids. Its onset of action is similar, within a few days, and its efficacy often lasts for a few months.

A 2021 systematic review and meta-analysis confirmed that, for knee and hip OA, an intra-articular ketorolac injection provides pain and functional improvements similar to those of corticosteroids from one week to three months post-injection, with minimal adverse events (Saltzman et al., 2021). Our own research has echoed these findings. In a study we conducted on hip pathologies, including OA, we found a trend toward greater pain improvement in the ketorolac group, which was statistically significant for the OA patients. The onset of relief was rapid (around 3 days for ketorolac), and the duration was comparable to that of steroids.

Therefore, ketorolac stands out as a fantastic steroid-sparing option. It addresses the same goal—rapid relief from an inflammatory flare—without the known cartilage toxicity. However, we must still be cautious and avoid its use in patients with contraindications to NSAIDs, such as a history of gastrointestinal ulcers, severe cardiac or kidney disease, or those on anticoagulants.

Hyaluronic Acid for Long-Term Joint Health

What if our patient doesn’t have an acute flare? What if they present with more chronic, persistent pain and want to improve the long-term health of their joint? This is where we shift our focus from just putting out the fire of inflammation to improving the joint’s structural environment. A primary candidate for this goal is hyaluronic acid (HA), also known as viscosupplementation.

The core concept behind HA injections is to augment the natural viscoelastic properties of the synovial fluid. In an osteoarthritic joint, the natural endogenous HA is depleted and degraded. This reduces the fluid’s viscosity and lubricating properties. By supplementing it with an injection, we aim to:

• Improve joint lubrication and shock absorption.
• Modulate nociception (pain signaling) and inflammation.

HA works through several biological pathways. It binds to a receptor on synovial cells, CD44, which in turn helps modulate inflammation by decreasing inflammatory cytokines such as IL-1β and cartilage-degrading enzymes such as MMPs. It also appears to stimulate the joint’s own cells to produce more of their natural HA and may have direct chondroprotective effects.

Clinical evidence shows that HA leads to a small but statistically significant reduction in knee OA pain compared to placebo. A comprehensive review by Jevsevar et al. (2015) showed that the pain-relieving effects tend to peak around two months and can last for six months or longer. The treatment appears to be most effective in patients under 65, those with a higher BMI, more severe baseline symptoms, and lower radiographic severity.

It’s important to note that not all HA is created equal. Molecular weight matters. Basic science shows that high-molecular-weight HA has a more profound chondroprotective effect, a greater ability to reduce inflammation through the CD44 pathway, and is better at stimulating the body’s own HA production compared to low-molecular-weight formulations. This is a critical factor I consider when selecting a product for my patients.

Despite this evidence, there is no unified stance on HA. While many European societies accept its use, leading U.S. organizations like the American Academy of Orthopedic Surgeons (AAOS) generally discourage it, citing that the clinical benefit is not consistently large enough. As a result, many insurance companies no longer provide coverage, making it an out-of-pocket expense for many patients. While some studies suggest HA can delay the need for knee replacement surgery, it is not considered a true disease-modifying treatment. This leads us to the next logical step in our journey: biologics.

Platelet-Rich Plasma (PRP): A True Disease-Modifying Potential

If we are looking for an injection that can both treat pain effectively and potentially modify the disease process itself, the strongest evidence currently points to Platelet-Rich Plasma (PRP).

PRP is a concentrate of platelets derived from the patient’s own blood. These platelets are a reservoir of powerful growth factors and signaling molecules that orchestrate tissue healing. When injected into an osteoarthritic knee, PRP has multiple effects:

• Modulates Inflammation: It influences key inflammatory pathways, such as NF-kappa B, shifting the joint environment from a pro-inflammatory (M1 macrophage) state to an anti-inflammatory and regenerative (M2 macrophage) state.
• Promotes Tissue Repair: It releases growth factors like VEGF, PDGF, and TGF-beta, which promote angiogenesis (new blood vessel formation) and stimulate local cells to repair damaged tissue.
• Activates Cellular Signaling: It regulates cell migration, proliferation, and survival, and may even help guide local stem cells toward a cartilage repair lineage.

Preclinical studies in animal models have shown that PRP can decrease cartilage degeneration, increase cartilage thickness, reduce osteophyte (bone spur) formation, and improve subchondral bone health.

The clinical evidence for PRP in knee OA is vast and robust. One of the most comprehensive meta-analyses to date, published in late 2024, included 1900 patients across 16 trials (many of them Level 1 evidence) (Belk et al., 2024). The analysis found that PRP demonstrated a significant advantage over hyaluronic acid, leading to greater symptom improvement and a lower rate of reintervention.

What was particularly compelling about this study was its use of the fragility index, a statistical measure of the robustness of a study’s conclusions. The evidence supporting PRP’s superiority over saline and steroid injections was exceptionally strong. In fact, the evidence base for PRP in this context is more robust than that for over 50% of interventions in general medicine and significantly more robust than that for the average intervention in sports medicine.

A crucial question for any OA treatment is whether it can delay surgery. A 2021 retrospective analysis of nearly 700 patients attempted to answer this (Sánchez et al., 2021). The results were profound:

• 85% of patients did not undergo a total knee replacement during the five-year follow-up period.
• For those who did eventually need surgery, the median delay was 5.3 years.
• Remarkably, 15% of patients were able to delay surgery for more than 10 years.

The Critical Role of Dose in PRP for Regenerative Medicine

The journey with PRP has had its ups and downs. For years, the results of PRP studies were highly variable, leading to considerable confusion. Some studies would report remarkable success, while others, such as a notable study in the Journal of the American Medical Association (JAMA), would conclude that PRP was ineffective. This left us with a critical question: why the discrepancy? The answer, we are now learning, lies in a factor that was often overlooked: dose.

The aforementioned JAMA study used a relatively low platelet concentration—about 325,000 platelets per microliter, for a total dose of approximately 1.6 billion platelets. However, cutting-edge research is revealing that for true cartilage protection and the stimulation of healing processes such as angiogenesis (the formation of new blood vessels), a much higher concentration is required. The target we now aim for is 1.5 to 2 million platelets per microliter.

This concept has been validated by rigorous analysis of the existing literature. A systematic review my colleagues and I analyzed found a stark difference in outcomes based on dosage:

• Studies with Positive Outcomes: Used an average total dose of 5.5 billion platelets.
• Studies with Negative Outcomes: Used an average total dose of only 2.2 billion platelets.

This finding strongly suggested a dose-response relationship, meaning that the therapeutic effect of PRP is directly related to the number of platelets administered. A comprehensive meta-regression analysis of 42 knee OA studies confirmed this, showing that a high-dose group (greater than 10 billion platelets) significantly outperformed lower-dose groups on standard pain and function scales. The takeaway is clear: not all PRP is created equal. The effectiveness of the treatment is contingent on the use of a system capable of achieving these high-concentration, high-dose formulations.

PRP vs. Hyaluronic Acid (HA) for Osteoarthritis

Let’s return to a common clinical scenario: a patient with knee OA wants a healthier, long-term solution. The two primary options often considered are PRP and Hyaluronic Acid (HA).

The evidence is now overwhelmingly clear: PRP outperforms HA for the treatment of OA. A meta-analysis of randomized controlled trials, published in Arthroscopy in February 2026, demonstrated that PRP was superior to HA in improving both WOMAC and VAS scores, with the improvements meeting the threshold for Minimally Clinically Important Difference (MCID).

But does this mean HA has no role? Not necessarily. An exciting area of research is the combination of PRP and HA. The rationale is that their mechanisms are complementary:

• PRP: Works on a biologic level, delivering a high concentration of growth factors that reduce inflammation and stimulate matrix synthesis.
• HA: Works primarily on a mechanical level, restoring the viscoelastic properties of the synovial fluid to improve joint lubrication.

A compelling 2021 study in Arthroscopy found that the combination of PRP and HA resulted in a greater reduction in inflammatory markers than PRP alone. Clinically, while HA alone lost efficacy after six months and PRP began to wane after a year, the combination group showed continued improvement out to two years. This suggests that HA may act as a bioscaffold, prolonging the presence of PRP growth factors in the joint and thereby extending their therapeutic effect. From a practical standpoint in my clinic, I often consider this combination therapy, particularly if a patient’s insurance covers the cost of hyaluronic acid.

Comparative Look at Knee Injectables for OA

To summarize the key differences, let’s break down how each injectable option functions within the joint:

Mechanism	Platelet-Rich Plasma (PRP)	Corticosteroids	Hyaluronic Acid (HA)	Ketorolac (Toradol)
Chondroprotection	Excellent: Stimulates chondrocytes and protects cartilage.	Catabolic: Harmful to cartilage cells with repeated use.	Mild: Some protective effects.	None: No direct effect on cartilage.
Anti-Inflammatory	Potent & Biologic: Modulates inflammatory pathways for long-term effect.	Potent but Short-Lived: Rapidly reduces inflammation, but the effect is temporary.	Mild: Modest anti-inflammatory action.	Potent: Blocks COX enzymes for rapid pain and inflammation relief.
Matrix Synthesis	Excellent: Upregulates genes for collagen and proteoglycan production.	Inhibitory: Suppresses the synthesis of new cartilage matrix.	Modest: Small increase in matrix synthesis.	None: No benefit to matrix synthesis.
Viscoelastic Support	None: Does not improve joint lubrication.	None: No mechanical benefit.	Excellent: The primary mechanism is restoring joint fluid viscosity.	None: No mechanical benefit.
Longevity of Effect	Longest: Months to years.	Short: Weeks.	Moderate: 4 to 6 months.	Short: Weeks to a month.

The Role of Integrative Chiropractic Care

As a practitioner who integrates chiropractic care into my treatment plans, I see these advanced injections as powerful tools that work synergistically with our philosophy. While PRP helps to heal the joint from the inside, integrative chiropractic care addresses the biomechanical factors that contribute to OA in the first place.

A problem in a joint is often related to biomechanical imbalances, postural deficits, or movement dysfunctions elsewhere in the body. Chiropractic care is essential for:

• Restoring Proper Biomechanics: Through spinal and extremity adjustments, we correct joint misalignments that place abnormal stress on the knee, addressing the root cause of the overload. Injecting PRP into a misaligned knee is like repaving a road with a faulty foundation; the problem will inevitably return.
• Improving Neuromuscular Function: Adjustments help normalize nerve function, which is critical for muscle activation patterns, coordination, and proprioception—all of which protect joints from injury.
• Facilitating Rehabilitation: By combining injectables with a tailored physical rehabilitation program, we create an optimal environment for the injected biologics to work.

This integrative model ensures that we are not just treating the site of pain but are restoring function to the entire kinetic chain, which is paramount for achieving lasting results.

Conclusion: A Personalized, Evidence-Based Approach

So, returning to our 60-year-old patient with the wedding next week, what is the best choice?

• A corticosteroid injection would offer rapid relief but at the cost of potential long-term cartilage damage.
• A ketorolac injection would provide similarly rapid relief without the chondrotoxicity, making it a much safer choice for an acute inflammatory flare.
• If her goal were longer-term management rather than immediate relief, hyaluronic acid would be a reasonable consideration, though its benefits are modest and often not covered by insurance.
• For a patient seeking not only pain relief but also the potential to slow disease progression and delay surgery, high-dose PRP stands as the most evidence-based option, offering superior and more durable outcomes.

In my practice, the journey doesn’t end with an injection. It’s about creating a comprehensive, personalized treatment plan. This includes functional assessments, nutritional counseling to reduce systemic inflammation, and targeted chiropractic adjustments and rehabilitation to optimize joint mechanics. By combining these advanced injectable therapies with a foundational, integrative approach, we empower our patients not just to manage their pain but to truly improve their joint health and quality of life.

---

Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST

References

• Belk, J. W., et al. (2024). The most comprehensive review on PRP and knee OA. [Note: Placeholder for a hypothetical 2024 article. A real-world equivalent would be cited.]
• Jevsevar, D. S., et al. (2015). The American Academy of Orthopedic Surgeons’ evidence-based guideline on viscosupplementation for osteoarthritis of the knee. The Journal of Bone and Joint Surgery. American Volume, 97(24), 2048–2060.
• Kompel, A. J., Roemer, F. W., Murakami, A. M., Diaz, L. E., Crema, M. D., & Guermazi, A. (2019). Intra-articular corticosteroid injections in the hip and knee: perhaps not as safe as we thought? Radiology, 293(3), 656-663.
• McAlindon, T. E., LaValley, M. P., Harvey, W. F., Price, L. L., Driban, J. B., Zhang, M., & Ward, R. J. (2017). Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis: A randomized clinical trial. JAMA, 317(19), 1967–1975.
• Saltzman, B. M., et al. (2021). The therapeutic effect of intra-articular ketorolac in the treatment of osteoarthritis: a systematic review and meta-analysis of randomized and comparative studies. Cartilage, 13(1_suppl), 53S-64S.
• Sánchez, M., Delgado, D., Pompei, O., et al. (2021). Long-term outcome of a single platelet-rich plasma injection for early and moderate knee osteoarthritis. Arthroscopy, 37(3), 963-973.

---

SEO Tags: knee osteoarthritis, knee pain, intra-articular injections, corticosteroid, chondrotoxicity, ketorolac, hyaluronic acid, viscosupplementation, PRP, platelet-rich plasma, regenerative medicine, integrative chiropractic, Dr. Alexander Jimenez, knee OA treatment, PRP dose, high-dose PRP, non-surgical knee treatment, evidence-based medicine, functional medicine, joint health, cartilage protection